Back to top

The Zacks Analyst Blog Highlights: Lockheed Martin, Allergan, Barclays, Constellation Brands and Southwest Airlines

Read MoreHide Full Article

For Immediate Release

Chicago, IL – March 14, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Lockheed Martin (LMT - Free Report) , Allergan (AGN - Free Report) , Barclays (BCS - Free Report) , Constellation Brands (STZ - Free Report) and Southwest Airlines (LUV - Free Report) .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Tuesday’s Analyst Blog:

Top Analyst Reports for Lockheed Martin, Allergan and Barclays

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Lockheed Martin, Allergan and Barclays. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Lockheed Martin’s shares have gained +24.3% over the last year, underperforming the Zacks Aerospace Defense sector, which has gained +47.3% over the same period. However, Lockheed Martin, being the largest defense contractor in the world, experiences strong demand for high-end military equipment in both domestic as well as overseas markets.

The Sikorsky takeover has proved to be beneficial for the company, in terms of substantial contract wins for production of newly designed choppers as well as maintenance of the existing one. In fact, strong order growth has been a primary growth driver for this company. Lockheed Martin continues to be a strong cash generator, helping it to take important cash deployment decisions.

However, the F-35 program, despite being a prime defense project for the U.S. government, has been facing criticism for being overly expensive for past few years. The company also faces intense competition for its broad portfolio of products and services in both domestic and international markets.

(You can read the full research report on Lockheed Martin here >>>).

Shares ofAllergan have lost -3.2% year to date, marginally underperforming the Zacks Generic Drugs industry, which has declined -3.0% over the same period. Allergan boasts dominant growth franchises across several therapeutic areas.

Key products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. Allergan also boasts a strong branded pipeline with meaningful data readouts expected in 2018. Biosimilars also represent significant opportunity.

However, while the Zacks analyst remains optimistic about the company’s growth prospects, Allergan faces potential loss of exclusivity for many products in 2018 including Namenda XR and Restasis. Also, competition for key growth drivers, Restasis and Linzess, is an investor concern. Nonetheless, in late 2017, Allergan announced cost-cutting initiatives to protect it from potential revenue declines.

(You can read the full research report on Allergan here >>>).

Barclays’s shares have outperformed the Zacks Foreign Banks industry over the last six months, with BCS shares up +17.7% vs. +5.1% gain for the industry. The company has surpassed expectations for earnings in only one of the trailing four quarters. The bank’s fourth quarter 2017 results reflected a slight improvement in revenues and lower expenses.

However, the Zacks analyst thinks restructuring and business simplifying efforts have ended successfully and will likely continue to result in decrease in expenses. Also, driven by these efforts, the company intends to enhance capital deployment activities as profitability improves going forward.

The bank has been facing pressure on revenues owing to weak capital market performance, low interest rates and uncertainty related to Brexit. Further, litigation matters remain a near-term concern.

(You can read the full research report on Barclays here >>>).

Other noteworthy reports we are featuring today include Constellation Brands and Southwest Airlines.

Zacks Top 10 Stocks for 2018

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?

Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2018 today >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit or information about the performance numbers displayed in this press release.

More from Zacks Press Releases

You May Like